SEATTLE, Oct. 17, 2011 /PRNewswire/ - Christopher Henney, Chairman of the Board
of Oncothyreon Inc. (Nasdaq: ONTY) and of Anthera Pharmaceuticals
(Nasdaq: ANTH) and Vice Chairman of the Board of Cyclacel
Pharmaceuticals, Inc. (Nasdaq: CYCC), received this year's Hall of Fame
- special recognition of outstanding individual contributions award at
the annual Biotech CEO Meeting at Laguna Beach.
Henney, the co founder of Immunex, ICOS and Dendreon corporations was
recognized for his contributions to the development of those companies'
leading products, Enbrel, Cialis and Provenge, all amongst the
industry's most important biopharmaceuticals.
Henney, a native of England, came to the biotech industry from an
earlier career as an academic immunologist at Johns Hopkins School of
Medicine. He served as the first Head of Immunology at the Fred
Hutchinson Cancer Center. Dr. Henney received a Ph.D. in experimental
pathology from the University of Birmingham, England, where he also
obtained his D.Sc. for contributions in the field of immunology.
Oncothyreon is a biotechnology company specializing in the development
of innovative therapeutic products for the treatment of cancer.
Oncothyreon's goal is to develop and commercialize novel synthetic
vaccines and targeted small molecules that have the potential to
improve the lives and outcomes of cancer patients. For more
information, visit www.oncothyreon.com.
SOURCE Oncothyreon Inc.